Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats

Pharmacological Research

Volumn 47, Issue 4, 2003, Pages 317-322

  Fadillioǧlu, Ersin ^a   Erdoǧan, Hasan ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Doxorubicin; Erdosteine; Lipid peroxidation; Oxidants

Indexed keywords

ANTIOXIDANT; CATALASE; DOXORUBICIN; ERDOSTEINE; GLUTATHIONE PEROXIDASE; MUCOLYTIC AGENT; NITRIC OXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LEVEL; CELL PROTECTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS;

EID: 0037376343     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00010-0     Document Type: Article

References (28)

1. Kang J.-K., Lee Y.-J., No K.-O., Jung E.-Y., Sung J.-H., Kim Y.-B.et al. Ginseng intestinal metabolite-I (GIM-I) reduces doxorubicin toxicity in the mouse testis. Reprod. Toxicol. 16:2002;291-298.
2. Wasptra F.H., van Goor H., de Jong P.E., Navis G., de Zeeuw D. Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. J. Pharmacol. Toxicol. 41:1999;69-73.
3. Dalledonne I., Milzani A., Colombo R. Dxr depresses the α-actinin-induced formation of actin bundles. Cancer Biochem. Biophys. 13:1993;245-254.
4. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity analysis of prevailing hypotheses. FASEB J. 4:1990;3076-3086.
5. Yu T.-W., Anderson D. Reactive oxygen species-induced DNA damage and its modification: a chemical investigation. Mutat. Res. 379:1997;201-210.
6. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S.et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;995-1005.
7. Fadillioglu E., Erdogan H., Polat A., Emre M.H. Renal antioxidant status in rats with hypertension induced by N sup omega nitro-L-arginine methyl ester. Kidney Blood Pres. Res. 25:2002;211-216.
8. Sayed-Ahmed M.M., Khattab M.M., Gad M.Z., Osman A.M. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol. Toxicol. 89:2001;140-144.
9. Venditti P., Balestrieri M., De Leo T., Di Meo S. Free radical involvement in doxorubucin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc. Res. 38:1998;695-702.
10. Korac B., Buzadzic B. Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. J. Dermatol. Sci. 25:2001;45-52.
11. Thabrew M.I., Samarawickrema N.A., Chandrasena L.G., Jayasekera S. Protection by garlic against adriamycin induced alterations in the oxido-reductive status of mouse red blood cells. Phytother. Res. 14:2000;215-217.
12. Braga P.C., Sasso M.D., Zuccotti T. Assesment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Drug Res. 50:2000;739-746.
13. Dechant K.L., Noble S. Erdosteine. Drug. 52:1996;875-881.
14. Gazzani G., Fregnan G.B., Vandoni G. In vitro protection by erdosteine against oxidative inactivation of alpha-1-antitrypsin by cigarette smoke. Respiration. 55:1989;113-118.
15. Braga P.C., Sasso M.D., Sala M.T., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Drug Res. 49:1999;344-350.
16. Aebi H. Catalase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press; 1974. p. 673-7.
17. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:1967;158-170.
18. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. In: Packer L, Glazer AN, editors. Methods in enzymology: V 186, oxygen radicals in biological systems. California: Academic Press; 1990. p. 407-21.
19. Sun Y., Oberley L.W., Li Y. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34:1988;497-500.
20. Durak I., Yurtarslanl Z., Canbolat O., Akyol O. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. Clin. Chim. Acta. 214:1993;103-104.
21. Cortas N.K., Wakid N.W. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin. Chem. 36:1990;1440-1443.
22. Prajda N., Weber G. Malign transformation-linked imbalance: decreased XO activity in hepatomas. FEBS Lett. 59:1975;245-249.
23. De Beer E.L., Bottone A.E., Voest E.E. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur. J. Pharmacol. 415:2001;1-11.
24. Vaidyanathan S., Boroujerdi M. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. Cancer Chemother. Pharmacol. 46:2000;93-100.
25. Esterbauer H. Cytotoxicity and genotoxicity of lipid peroxidation products. Am. J. Clin. Nutr. 57(5 Suppl):1993;779-785.
26. Arancia G., Bordi F., Calcabrini A., Diociaiuti M., Molinari A. Ultrastructural and spectroscopic methods in the study of anthracyclines-membrane interaction. Pharmacol. Res. 32:1995;255-272.
27. Fadillioglu E., Erdogan H., Sogut S., Kuku I. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats. J. Appl. Toxicol. 23:2003;71-74.
28. Yildirim Z., Sogut S., Odaci E., Iraz M., Ozyurt H., Kotuk M.et al. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol. Res. 47:2003;149-156.